Merck ADC, licensed from China, hits mark in first big global trial
BioPharma Dive
The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that s important to its ambitions of hitting $70 billion in annual sales next decade.
pharminent
May 18, 2026 (Last updated: May 19, 2026)
BioPharma Dive
The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that s important to its ambitions of hitting $70 billion in annual sales next decade.
